MODIFY I/II
2017
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
In 2,655 patients receiving antibiotics for Clostridium difficile infection, a single dose of bezlotoxumab reduced recurrent CDI at 12 weeks compared with placebo.
Result
Primary endpoint: Recurrent CDI at 12 weeks
Recurrence 17 % vs 28 % (MODIFY I) and 16 % vs 26 % (MODIFY II); ARR ~10 pp; NNT ≈ 10.
- Subtopic
- Recurrence prevention
- Design
- Two double-blind RCTs (pooled)
- Relevance
- Supporting: context rather than must-know.
- Source
- Wilcox MH, et al. N Engl J Med. 2017;376(4):305-317.doi 10.1056/NEJMoa1602615
Discussion & critique
Bezlotoxumab as adjunctive recurrence prevention: most useful in patients ≥65 years, immunocompromised or with severe or repeated CDI.